The Managed Care Review Board™ Examining the Impact of Oral Immunotherapy Tablets on Allergy Immunotherapy — Web Activity

• Release date: January 2015
• Expiration date: July 31, 2016
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with (IE 6 and up, Firefox, Safari)

DISTINGUISHED FACULTY

David I. Bernstein, MD Professor of Medicine and Environmental Health Division of Immunology, Allergy and Rheumatology University of Cincinnati College of Medicine Click here for biography

Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography John Fox, MD, MHA Senior Medical Director Associate Vice President, Medical Affairs Priority Health Click here for biography Fadia T. Shaya, PhD, MPH Professor and Vice-Chair for Academic Affairs Director of Research, CIPS University of Maryland School of Pharmacy Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for allergen immunotherapy: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

This educational initiative is designed to address managed care professionals’ need to evaluate evolving allergy immunotherapy treatment protocols and benefit design methodologies to improve outcomes for health plan patients impacted by allergic diseases.  The purpose of the activity is to increase the competence and performance of the audience by enhancing results of their own organizations’ systematic reviews and analyses on the impact of emerging oral immunotherapy as compared to subcutaneous injection.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Recommend allergen immunotherapy treatment strategies in accordance with current AAAAI guidelines
• Review the underlying pathophysiology of allergic rhinitis and the immune response that is generated against specific allergens
• Assess recent clinical data on the risks and benefits of allergen immunotherapy for patients with allergic symptoms of rhinitis or conjunctivitis
• Evaluate the patient preferences regarding oral immunotherapy for allergies
• Outline the direct and substantial indirect costs related to allergic disease as a leading cause of absenteeism and productivity loss in the workplace
• Apply benefit design methodologies that MCOs can implement to improve the overall value for allergy immunotherapy

AGENDA

Introduction
Jeffrey D. Dunn, PharmD, MBA

Clinical Benefits Overview and Practice Guidelines Review
David I. Bernstein, MD

Treatment Options Analysis
Jeffrey D. Dunn, PharmD, MBA

Health Economics and Pharmacoeconomics Assessment
Fadia T. Shaya, PhD, MPH

Benefit Design Considerations
John Fox, MD, MHA

Faculty Idea Exchange
Closing Comments

ACCREDITATION

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Impact Education, LLC.  MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement

	Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number – 0816-9999-14-009-H02-P)

This activity is certified as knowledge based CPE.

Nursing Continuing Education
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.5 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider # CEP 12299, for 1.5 contact hours.

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Merck & Co., Inc.  The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Impact Education, LLC., and/or Merck & Co., Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving credit for this activity. During the period January 2015 through July 31, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.

MER Privacy Policy